Formulary guidance and transparency from P&T to point of care


Reality Check on Ovarian Cancer

Market access for ovarian cancer treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.  

To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:

  • Payer Insights: Across all drugs in the class, only an average of 17% of Medicare lives are not covered for at least one of the drugs 
  • Class Trends: The FDA in June expanded the label of Avastin (bevacizumab) to include its use in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, for the treatment of stage III or stage IV epithelial ovarian, fallopian tube or primary peritoneal cancer following initial surgery resection
  • Key Findings: There are more than 10 FDA-approved products to treat varying stages of ovarian cancer, and 13 agents in last-stage development. This is and will continue to be a crowded market

What can pharma do to curb this trend and overcome these challenges?

Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.

Download the full Reality Check now.